| 引用本文: | 曾愫琦,邓蓓莹,张吉翔,董卫国.炎症性肠病患者对抗肿瘤坏死因子-α单克隆抗体原发性失应答研究进展[J].中国现代应用药学,2022,39(23):3159-3163. |
| ZENG Suqi,DENG Beiying,ZHANG Jixiang,DONG Weiguo.Research Progress of Primary Non-response to Anti-TNF-α Monoclonal Antibody in Patients with Inflammatory Bowel Disease[J].Chin J Mod Appl Pharm(中国现代应用药学),2022,39(23):3159-3163. |
|
| 摘要: |
| 抗肿瘤坏死因子(TNF)-a单克隆抗体(单抗)现已广泛用于治疗激素依赖或难治性炎症性肠病(inflammatory bowel disease，IBD)患者，然而部分患者在治疗期间会出现原发性无应答。本综述就接受抗TNF-α单抗治疗的IBD患者发生原发性失应答的机制、预测标志物总结了目前相关研究进展，为实现IBD生物制剂治疗的精确化、个体化提供理论依据。 |
| 关键词: 炎症性肠病 抗肿瘤坏死因子 原发性失应答 |
| DOI：10.13748/j.cnki.issn1007-7693.2022.23.017 |
| 分类号:R969.3 |
| 基金项目:国家自然科学基金项目(81870392) |
|
| Research Progress of Primary Non-response to Anti-TNF-α Monoclonal Antibody in Patients with Inflammatory Bowel Disease |
|
ZENG Suqi, DENG Beiying, ZHANG Jixiang, DONG Weiguo
|
|
Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan 430060, China
|
| Abstract: |
| Anti-tumor necrosis factor-a(anti-TNF-a) monoclonal antibodies are now widely used in patients with steroid-dependent or steroid-refractory inflammatory bowel disease(IBD). However, some patients will experience primary non-response(PNR) during treatment. This review summarized the current research progress on the mechanism and predictive markers of PNR in IBD patients treated with anti-TNF-α monoclonal antibodies, providing a theoretical basis for the realization of precise and individualized treatment of IBD biologics. |
| Key words: inflammatory bowel disease anti-tumor necrosis factor primary non-response |
